Advances in the treatment of early rheumatoid arthritis

American Family Physician

Volumn 72, Issue 6, 2005, Pages 1002-1005

  Vital, Edward M J ^a   Emery, Paul ^b,c  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT;

CLINICAL TRIAL; EDITORIAL; HUMAN; INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT; PROGNOSIS; RADIOGRAPHY; RHEUMATOID ARTHRITIS; SYMPTOM; ULTRASOUND; UNSPECIFIED SIDE EFFECT; DRUG ADMINISTRATION; NOTE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; HUMANS; PROGNOSIS;

EID: 26944458560     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Editorial

References (12)

1. Rat AC, Boissier MC. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine 2004;71:518-24.
2. Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am Fam Physician 2005;72:1037-47.
3. Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003;21(5 suppl 31):S154-7.
4. McGonagle D, Conaghan PG, O'Connor P, Gibbon W, Green M, Wakefield R, et al. The relationship between synovitis and bone changes in early untreated rheumatoid arthritis: a controlled magnetic resonance imaging study. Arthritis Rheum 1999;42:1706-11.
5. McQueen FM, Benton N, Crabbe J, Robinson E, Yeoman S, McLean L, et al. What is the fate of erosions in early rheumatoid arthritis? Tracking individual lesions using x-rays and magnetic resonance imaging over the first two years of disease. Ann Rheum Dis 2001;60:859-68.
6. Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilosen J, et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002;46:894-8.
7. Guillemin F, Gerard N, van Leeuwen M, Smedstad LM, Kvein TK, van den Heuvel W, et al. Prognostic factors for joint destruction in rheumatoid arthritis: a prospective longitudinal study of 318 patients. J Rheumatol 2003;30:2585-9.
8. Wakefield, RJ, Gibbon WW, Conaghan PG, O'Connor P, McGonagle D, Pease C, et al. The value of sonography in the detection of bone erosion in patients with rheumatoid arthritis: a comparative study with conventional radiography. Arthritis Rheum 2000;43:2762-70.
9. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
10. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73.
11. Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
12. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.